Publication date: May 22, 2025
“By specifically targeting VTA activity and connectivity, ezogabine could open the door to decidedly improved outcomes for people who struggle daily with depression and anhedonia. Murrough is a named inventor on a pending patent application for the use of ezogabine and other KCNQ channel openers to treat depression and related disorders. “This hypothesis will require confirmation in larger clinical trials. “Dr.
| Concepts | Keywords |
|---|---|
| Depressive | Activity |
| Food | Anhedonia |
| Neuroscience | Brain |
| Potassium | Channel |
| Depression | |
| Ezogabine | |
| Kcnq | |
| Mount | |
| Murrough | |
| Provide | |
| Psychiatry | |
| Published | |
| Sinai | |
| Targeting | |
| Treatment |
Semantics
| Type | Source | Name |
|---|---|---|
| pathway | REACTOME | Release |
| drug | DRUGBANK | Dopamine |
| disease | MESH | anhedonia |
| disease | MESH | seizures |
| disease | MESH | epilepsy |
| disease | MESH | Anxiety |
| drug | DRUGBANK | Ezogabine |
| disease | MESH | major depressive disorder |
| pathway | REACTOME | Potassium Channels |
| disease | MESH | depression |
Original Article
(Visited 1 times, 1 visits today)